ArticleMolecular metabolism2026
A UFMylation-COPII axis orchestrates lipid transport in intestinal enterocytes and regulates systemic lipid balance.
Article in Molecular metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntestinal lipid absorption and chylomicron secretion are essential for systemic lipid homeostasis, yet the regulatory mechanisms coordinating lipoprotein assembly and ER export remain poorly understood. UFMylation is a newly identified ubiquitin-like modification pathway that plays critical roles in endoplasmic reticulum (ER)-related cellular activities such as protein quality control, ER-associated degradation (ERAD) and ER-phagy. However, its role in intestinal lipid transport and systemic lipid homeostasis is completely unclear.
methodsTo elucidate the role of UFMylation in intestinal lipid metabolism, we generated intestinal epithelial cell (IEC)-specific knockout mouse model of Ufbp1, a key component of the UFMylation pathway, and a double knockout model of Ufbp1 and IRE1α, one of the three signaling branches of Unfolded Protein response (UPR). After observing lipid droplet accumulation in the intestinal tissue of Ufbp1 and IRE1α double knockout mice, we further examined lipid metabolism in Ufbp1 knockout mice under high-fat diet. Finally, we used C2BBe1, a subclone of Caco-2 cell, as a cell model to investigate the role of UFMylation in Coat Protein Complex II (COPII)-mediated lipid transport in enterocytes.
resultsWe serendipitously found that the combination of Ufbp1 and IRE1α deficiencies led to dramatic accumulation of lipid droplets in the enterocytes, thereby impairing enterocyte function and causing significant growth retardation. Furthermore, we found that Ufbp1 IEC-specific knockout mice were highly resistant to high-fat diet-induced hyperlipidemia. On the molecular level, we found that the components of the UFMylation pathway interacted with COPII complex and regulates the recruitment of COPII coat to ER-located lipoprotein.
conclusionsOur findings have established that the UFMylation pathway is a novel mediator of enterocyte lipid transport and a key partner of COPII-mediated trafficking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.